adrenomyeloneuropathy


Also found in: Dictionary, Acronyms, Wikipedia.
Related to adrenomyeloneuropathy: adrenoleukodystrophy

a·dre·no·my·e·lo·neu·rop·a·thy

(ă-drē'nō-mī'ĕ-lō-nū-rop'ă-thē),
A disorder of men, consisting of long-standing adrenal insufficiency, hypogonadism, progressive myelopathy, peripheral neuropathy, and sphincter disturbances; considered a variant of adrenoleukodystrophy.
[adreno- + G. myelos, medulla, + neuron, nerve, + pathos, suffering]

adrenomyeloneuropathy

An X-linked recessive disorder characterised by a non-inflammatory distal axonopathy involving mainly spinal cord, long tracts and to a lesser extent, peripheral nerves. It is a nervous system manifestation of adrenoleukodystrophy.

Clinical findings
Slowly progressive diplegia; peripheral neuropathy with or without primary adrenal failure, as well as primary testicular failure; red-green colour blindness; and depression. It affects 1 in 20–100,000 males, most commonly as cerebral adrenoleukodystrophy in childhood or adrenomyeloneuropathy in adulthood.

ad·re·no·my·e·lo·neu·rop·a·thy

(ă-drē'nō-mī'ĕ-lō-nūr-op'ă-thē)
A disorder of men, consisting of long-standing adrenal insufficiency, hypogonadism, progressive myelopathy, peripheral neuropathy, and sphincter disturbances; considered a variant of adrenoleukodystrophy.
[adreno- + G. myelos, medulla, + neuron, nerve, + pathos, suffering]
References in periodicals archive ?
Clinical aspects of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci 1991;13:254-61.
Adrenomyeloneuropathy presenting as Addison's disease in childhood.
ReceptoPharm Inc., the drug-discovery holding of Nutra Pharma, is currently studying the effectiveness of Cobra Venom and Cobratoxin as treatments for Multiple Sclerosis, HIV, Adrenomyeloneuropathy (AMN), pain and rabies.
The China International Exchange and Promotive Association for Medical and Healthcare has granted notification of the acceptance to Nutra Pharma, a biotechnology company that is developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain, for its Nyloxin, it was reported on Friday.
Nutra Pharma Corp., which today announced that its ReceptoPharm drug candidate has received Ethics Committee approval in the UK to begin a Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN), is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases.
Patient 2 was a 51-year-old woman with adrenomyeloneuropathy. Her admission was for exclusion of adrenocortical insufficiency, which may occur in adrenomyeloneuropathy.
Patients with all clinical subtypes, including childhood ALD, adolescent ALD, adult ALD (cerebral type), adrenomyeloneuropathy, and Addison disease without neurological symptoms, have defects in the ALD gene [2].
The ratio was >1.5 in all ALD patients (1.8 [+ or -] 0.2) (10 with childhood ALD and 2 with adrenomyeloneuropathy) and in 6 of 7 carrier mothers (1.6 [+ or -] 0.2) (Fig.